Abstract 1529
Background
Elevated AFP in patients (pts) with HCC is associated with worse prognosis. Two placebo (P)-controlled trials (REACH, REACH-2) have studied ramucirumab (RAM, anti-VEGFR2 antibody) in pts with HCC after sorafenib, with REACH-2 enrolling only pts with baseline AFP ≥400 ng/mL. In REACH-2 RAM treatment (trt) improved overall survival (OS) compared to P, consistent with REACH (AFP ≥400 ng/mL) pts. Here we present post-hoc analyses assessing the prognostic and predictive value of baseline AFP in both studies.
Methods
Pts with HCC, Child-Pugh A, ECOG PS 0-1, and prior sorafenib were randomized to RAM 8 mg/kg or P Q2W. The prognostic value of baseline AFP was assessed by Cox regression models with either continuous or dichotomous (≥400 vs < 400 ng/ml) AFP (REACH, N = 565), and confirmed using Cox model with continuous AFP ≥400 ng/mL (REACH-2, N = 292). Cox model with AFP and its trt interaction assessed the predictive value of baseline AFP in REACH. Subpopulation trt effect pattern plot (STEPP) assessed the interaction between RAM trt and AFP in REACH, REACH-2 and pooled individual pt data analysis of both studies (AFP ≥400 mg/mL).
Results
Baseline AFP was confirmed as a significant continuous (REACH and REACH-2; p<.0001) and dichotomous (REACH; p<.01) prognostic factor for OS. AFP remained the predominant prognostic factor after adjusting for other significant prognostic factors, including macrovascular invasion and ECOG PS. The interaction between AFP and trt effect was significant in REACH (p=.0042 continuous; p<.0001 dichotomous), suggesting the predictive value of AFP in RAM OS benefit. Based on Cox regression of OS on continuous AFP level and its interaction with trt, the estimated OS hazard ratio in REACH (<0.8, 95% CI below 1) was significant at each AFP value ≥400 ng/mL, supporting AFP ≥400 ng/mL as selection criterion for RAM OS benefit. STEPP supported these results with OS benefits at each AFP value ≥400 ng/mL.
Conclusions
The prognostic impact of baseline AFP is an important factor to consider in trial design. The findings suggest AFP may be predictive of RAM OS benefit. Results also confirm AFP ≥400 ng/mL is appropriate selection criterion for RAM OS benefit.
Clinical trial identification
NCT01140347, NCT02435433.
Editorial acknowledgement
Nathalie Godinot, funded by Eli Lilly and Company.
Legal entity responsible for the study
Eli Lilly and Company.
Funding
Eli Lilly and Company.
Disclosure
A.X. Zhu: Advisory / Consultancy: Eisai; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Exelixis; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly and Company; Advisory / Consultancy: Roche/Genentech. P.R. Galle: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bayer Schering Pharma; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Sirtex Medical; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Eli Lilly and Company; Honoraria (self), Advisory / Consultancy: Bristol-Meyers Squibb; Advisory / Consultancy: MSD; Honoraria (self): Sillajen. J.M. Llovet: Advisory / Consultancy: Eli Lilly and Company; Advisory / Consultancy, Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Eisai; Advisory / Consultancy: Celsion; Advisory / Consultancy: Incyte; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Glycotest; Research grant / Funding (institution): Blueprint Medicines; Research grant / Funding (institution): Bayer Schering Pharma. R.S. Finn: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Roche Genentech; Advisory / Consultancy, Research grant / Funding (institution): Eisai; Advisory / Consultancy: Exelixis. Y. Kang: Advisory / Consultancy: Eli Lilly and Company; Advisory / Consultancy: Taiho Pharmaceutical; Advisory / Consultancy: Ono Pharmaceutical; Advisory / Consultancy: Roche Genentech; Advisory / Consultancy: Merck Serono; Advisory / Consultancy, Research grant / Funding (self): DAE HWA Pharmaceutical; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Astellas Pharma; Advisory / Consultancy, Research grant / Funding (self): LSK Biopharma. E. Assenat: Honoraria (self), Advisory / Consultancy: Ipsen; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Terasphere; Honoraria (self), Advisory / Consultancy: Sirtex Medical; Honoraria (self), Advisory / Consultancy: Sanofi; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Servier. G. Brandi: Advisory / Consultancy: Eli Lilly and Company. K. Motomura: Honoraria (self): Eisai. I. Ohno: Advisory / Consultancy: Merck Serono; Speaker Bureau / Expert testimony: Taiho Pharmaceutical. B. Daniele: Honoraria (self), Travel / Accommodation / Expenses: Bayer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Eisai; Honoraria (self): Eli Lilly; Honoraria (self), Advisory / Consultancy: Ipsen; Advisory / Consultancy: Incyte; Advisory / Consultancy: MSD; Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Travel / Accommodation / Expenses: Celgene. A. Vogel: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Novartis; Honoraria (self), Advisory / Consultancy: Delcath Systems; Honoraria (self), Advisory / Consultancy: Eli Lilly and Company; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bayer; Advisory / Consultancy: Baxalta; Travel / Accommodation / Expenses: Ipsen; Honoraria (self): Sanofi; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): MSD. T. Yamashita: Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony: Eisai. C. Hsu: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Ono Pharmaceutical; Advisory / Consultancy: Eli Lilly and Company; Advisory / Consultancy, Research grant / Funding (institution): MSD; Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Merck Serono; Honoraria (self), Travel / Accommodation / Expenses: Merck Sharp & Dohme; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Taiho Pharmaceutical. T. Meyer: Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Eisai; Advisory / Consultancy, Research grant / Funding (institution): Ipsen; Advisory / Consultancy: Tarveda Therapeutics; Advisory / Consultancy, Research grant / Funding (institution): BTG; Advisory / Consultancy: Beigene; Advisory / Consultancy: MSD; Research grant / Funding (institution): Bayer. R. Widau: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. W. Schelman: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. C. Wang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. Y. Hsu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Eli Lilly and Company. M. Kudo: Honoraria (self), Advisory / Consultancy: MSD; Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Eisai; Honoraria (self), Research grant / Funding (institution): AbbVie; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self): Gilead Sciences; Honoraria (self): Otsuka; Advisory / Consultancy, Research grant / Funding (institution): Daiichi Sankyo; Advisory / Consultancy: EA Pharma; Advisory / Consultancy, Research grant / Funding (institution): Astellas Pharma; Advisory / Consultancy, Research grant / Funding (institution): Chugai Pharma; Research grant / Funding (institution): Otsuka; Research grant / Funding (institution): Bristol-Myers Squibb Japan. All other authors have declared no conflicts of interest.
Resources from the same session
2107 - Role of Individualized Intervention(s) on Quality of Life (QOL) and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women with Early-Stage Breast Cancer (BC): MyChoice Study
Presenter: Shahid Ahmed
Session: Poster Display session 2
Resources:
Abstract
5812 - Correlation between the density of tumor-infiltrating lymphocytes, immune cell subsets in tumor stroma and response to systemic therapy in breast cancer
Presenter: Cvetka Grasic Kuhar
Session: Poster Display session 2
Resources:
Abstract
4734 - BRCA1/2 Testing in HER2- Advanced Breast Cancer (ABC): Results from the European Component of a Multi-Country Real World Study
Presenter: Michael Patrick Lux
Session: Poster Display session 2
Resources:
Abstract
1686 - In vitro and in vivo rescue of resistance to BET inhibitors by targeting PLK1 in triple negative breast cancer.
Presenter: Cristina Nieto-jiménez
Session: Poster Display session 2
Resources:
Abstract
5020 - Neoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
5082 - Melatonin and metformin in neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
2642 - Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach
Presenter: Anna Mueller-Schoell
Session: Poster Display session 2
Resources:
Abstract
2461 - Lack of benefit of neoadjuvant pertuzumab in high risk HER2 positive breast cancer. A retrospective case-control study of 355 cases with biomarker analysis.
Presenter: Manuela Tiako Meyo
Session: Poster Display session 2
Resources:
Abstract
4776 - Targeting CDCA3 to improve chemotherapy response in triple-negative breast cancer patients
Presenter: Kenneth O'Byrne
Session: Poster Display session 2
Resources:
Abstract
1674 - Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Presenter: María Del Mar Noblejas López
Session: Poster Display session 2
Resources:
Abstract